Vanda Pharmaceuticals appoints chief commercial officer

Bob Repella joins US biopharmaceutical firm

Vanda Pharmaceuticals has named Bob Repella as senior vice president and chief commercial officer of the US biopharmaceutical firm that specialises in clinical-stage products for CNS disorders.

Repella has more than 25 years of experience in the biotech/pharmaceutical industry, including senior-level leadership roles in global marketing, sales, new product development and commercial operations.

Prior to joining Vanda, he was senior vice president of Pharmaceutical Operations for the Americas at Cephalon.

Before this, Repella was executive vice president and general manager of the Biopharma Business Unit for Wyeth Pharmaceuticals.

Earlier in his career, Repella held positions with Johnson & Johnson's McNeil Pharmaceutical Division, Merck & Co and Eli Lilly.

You may also like